Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group

Roberto Cauda, Giovanni Fadda, Rosaria Santangelo, Manuela Colafigli, Andrea De Luca, Valentina Svicher, Claudia Alteri, Marco Montano, Roberta D'Arrigo, Massimo Andreoni, Gioacchino Angarano, Andrea Antinori, Guido Antonelli, Tiziano Allice, Patrizia Bagnarelli, Fausto Baldanti, Ada Bertoli, Marco Borderi, Enzo Boeri, Isabella BonBianca Bruzzone, Anna Paola Callegaro, Maria Rosaria Capobianchi, Giampiero Carosi, Francesca Ceccherini-Silberstein, Massimo Clementi, Antonio Chirianni, Antonella D'Arminio Monforte, Antonio Di Biagio, Giuseppe Di Nicuolo, Giovanni Di Perri, Massimo Di Pietro, Fabiola Di Santo, Lavinia Fabeni, Massimo Galli, William Gennari, Valeria Ghisetti, Andrea Giacometti, Caterina Gori, Andrea Gori, Roberto Gulminetti, Francesco Leoncini, Gaetano Maffongelli, Franco Maggiolo, Giuseppe Manca, Franco Gargiulo, Canio Martinelli, Renato Maserati, Francesco Mazzotta, Genny Meini, Valeria Micheli, Laura Monno, Cristina Mussini, Pasquale Narciso, Silvia Nozza, Stefania Paolucci, Giorgio Palù, Saverio Parisi, Giustino Parruti, Angela Rosa Pignataro, Michela Pollicita, Tiziana Quirino, Maria Re Carla, Giuliano Rizzardini, Renzo Scaggiante, Gaetana Sterrantino, Ombretta Turriziani, Maria Linda Vatteroni, Laura Vecchi, Claudio Viscoli, Vincenzo Vullo, Maurizio Zazzi, Adriano Lazzarin, Carlo Federico Perno

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

22 Citazioni (Scopus)

Abstract

OBJECTIVE: The DIVA study is aimed at setting up a standardized genotypic tropism-testing on proviral-DNA for the routine clinical diagnostic-laboratory. METHODS: Twelve local centres and 5 reference centres (previously cross-validated) were identified. For inter-center validation-procedure, 60 peripheral-blood mononuclear cells (PBMCs) aliquots from 45 HAART-treated patients were randomly chosen for population V3 sequencing on proviral-DNA at local HIV centre and at reference-laboratory. Viral tropism was predicted by Geno2Pheno algorithm (False Positive Rate [FPR] = 20%) as proposed by the European-Guidelines. Quantification of total HIV-1 DNA was based on a method described by Viard (2004). RESULTS: Quantification of HIV-1 DNA was available for 35/45 (77.8%) samples, and gave a median value of 598 (IQR:252- 1,203) copies/10 PBMCs. A total of 56/60 (93.3%) samples were successfully amplified by both the reference and the local virological centers. The overall concordance of tropism prediction between local and reference centers was 54/56 (96.4%). Results of tropism prediction by local centers were: 33/54 (61.1%) R5 and 21/54 (38.9%) X4/DM. CONCLUSION: There was high concordance in the genotypic tropism prediction based on proviral DNA among different virological centers throughout Italy. Our results are in line with other European studies, and support the use of genotypic tropism testing on proviral DNA in patients with suppressed plasma HIV-1 RNA candidate to CCR5-antagonist treatment.
Lingua originaleEnglish
pagine (da-a)17-25
Numero di pagine9
RivistaNew Microbiologica
Volume35
Stato di pubblicazionePubblicato - 2012

Keywords

  • Genotype
  • Genotyping Techniques
  • HIV Envelope Protein gp120
  • HIV Infections
  • HIV-1
  • Humans
  • Leukocytes, Mononuclear
  • Proviruses
  • Reproducibility of Results
  • Viral Load
  • Viral Tropism

Fingerprint Entra nei temi di ricerca di 'Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group'. Insieme formano una fingerprint unica.

Cita questo